Keyphrases
ABCG2 Transporter
14%
Abemaciclib
57%
Advanced Breast Cancer
14%
ATP Binding Cassette Subfamily B Member 1 (ABCB1)
14%
Bioanalysis
100%
Bioanalytical Methods
42%
Brain Penetration
14%
Cancer Therapy
14%
CDK2 Inhibitors
14%
CDK4/6 Inhibitor Palbociclib
14%
Clinical Application
14%
Clinical Pharmacology
28%
Clinically Significant
14%
Cyclin
14%
Cyclin-dependent Kinase
42%
Cyclin-dependent Kinase 4 (CDK4)
28%
Cyclin-dependent Kinase 6 (CDK6)
14%
Cyclin-dependent Kinase Inhibitor
100%
Cytochrome P450 3A Enzyme
14%
Cytochrome P450 3A4 (CYP3A4)
14%
Cytotoxic Drugs
14%
Drug Transporters
28%
Drug-metabolizing Enzymes
14%
Efficacy-toxicity
14%
Efflux
14%
European Medicines Agency Guideline
14%
Exposure-response
14%
Extrinsic Factors
14%
Food Effect
14%
Fuller Method
14%
Further Development
14%
Genetically Engineered Mouse Models
14%
Global Health Issue
14%
High Efficacy
14%
Improved Efficacy
14%
In Cancer
100%
Increased Safety
14%
Inter-individual Variability
14%
Malignancy
28%
Metabolism
14%
Metastatic Breast Cancer
14%
Method Validation
14%
Milciclib
28%
Normal Population
14%
Palbociclib
42%
Pharmacodynamics
28%
Pharmacokinetics
100%
Pharmacological Aspects
14%
Preclinical Investigation
14%
Promising Target
14%
Reduced Toxicity
14%
Ribociclib
57%
Specific Populations
14%
Substrate Drugs
14%
Targeted Cancer Therapy
14%
Tissue Distribution
14%
U.S. Food
14%
Uptake Transporter
14%
Pharmacology, Toxicology and Pharmaceutical Science
ABCG2
14%
Abemaciclib
57%
Anticancer Drug
14%
Breast Cancer
14%
Clinical Pharmacokinetics
28%
Clinical Study
28%
Cyclin Dependent Kinase
42%
Cyclin Dependent Kinase Inhibitor
100%
Cycline
14%
CYP3A
14%
CYP3A4
14%
Cytotoxic Agent
14%
Diseases
14%
Drug Metabolizing Enzyme
14%
Effusion
28%
Genetically Engineered Mouse Strain
14%
Malignant Neoplasm
100%
Metastatic Breast Cancer
14%
Milciclib
28%
Mouse Model
14%
Palbociclib
57%
Pharmacodynamics
28%
Pharmacokinetics
100%
Preclinical Study
14%
Ribociclib
57%
Vitamin B12
14%